Loading...
XSHE
000908
Market cap862mUSD
Jul 10, Last price  
6.75CNY
1D
0.90%
1Q
-6.25%
Jan 2017
-35.41%
Name

Hunan Jingfeng Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:000908 chart
P/E
P/S
15.61
EPS
Div Yield, %
Shrs. gr., 5y
0.01%
Rev. gr., 5y
-14.16%
Revenues
378m
-9.11%
216,801,752236,376,147217,389,628139,030,825943,802,6951,419,410,8791,957,430,0132,459,038,6802,640,503,6292,583,652,3342,585,696,9001,344,029,110877,918,598811,183,491811,183,490840,657,161840,657,161656,893,837416,031,776378,112,342
Net income
0k
-100.00%
002,991,7270149,682,914135,214,003251,029,278324,101,710340,028,583162,085,599186,812,667-882,806,462-1,068,514,8870-163,660,1870-122,563,621-236,100,438152,304,3180
CFO
59m
P
57,903,24152,264,93031,015,808000351,5010205,930,47092,367,54912,324,621151,650,408350,937,84536,170,4280123,834,599123,266,70135,063,943-5,550,95859,321,386
Dividend
Aug 23, 20180.01 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hunan Jingfeng Pharmaceutical Co.,Ltd., established in 2003 and headquartered in Shanghai, China, operates as a manufacturer and supplier of various pharmaceutical products, including chemical compounds and biological agents, within the Chinese market. A prominent offering from the company is its sodium hyaluronate injection, which finds extensive application in both orthopedic and surgical fields. Beyond this, their product range encompasses ophthalmology solutions and Active Pharmaceutical Ingredients (APIs). The firm also dedicates resources to the research and development of medications for anti-tumor, cancer, and cardiovascular conditions, alongside providing a selection of skincare products.
IPO date
Feb 03, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT